Drug intelligence / Profile preview

h1 virus-like particle influenza vaccine

Development stage
Unknown
Lead developer
Novavax
Modality
Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

A **h1 virus-like particle influenza vaccine** is a vaccine candidate that uses **virus-like particles (VLPs)** engineered to display the hemagglutinin (HA) and neuraminidase (NA) proteins of an H1 subtype influenza A virus. VLPs mimic the structure of native influenza virions but lack viral genomic RNA, making them non-infectious while still immunogenic. This modality can induce both humoral and cellular immune responses, including the generation of neutralizing antibodies against H1-HA and NA, as well as robust T-cell responses. VLP-based vaccines are under clinical investigation for their potential to yield broader and more durable immunity compared to traditional inactivated or split-virion influenza vaccines. They may also be formulated as bivalent or multivalent vaccines by combining VLPs representing multiple influenza subtypes.

Other names
H1 VLP influenza vaccineH-1 VLP influenza vaccineH 1 VLP influenza vaccineH1N1 VLP influenza vaccineH-1N1 VLP influenza vaccineH 1N1 VLP influenza vaccineInfluenza A H1N1 VLP vaccine
02

Targets

HA (Hemagglutinin)Neuraminidase

Beyond the preview

Go deeper on h1 virus-like particle influenza vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on h1 virus-like particle influenza vaccine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call